Exploring the science and data of microdosing, and briefing key drug interactions with the use of common used psychedelic therapies

References:

Cheung T. COMPASS Announces Positive Outcome of 25 mg COMP360 Psilocybin Therapy as Adjunct to SSRI Anti-depressant in Open-Label, Treatment-Resistant Depression Study. COMPASS Health. 13 Dec 2021 [press release].

Grinspoon P. The Popularity of Microdosing of Psychedelics: What Does the Science Say? Harvard Health. 19 Sept 2022.

Gukasyan N, et al. Attenuation of Psilocybin Mushroom Effects During and After SSRI/SNRI Anti-depressant Use. Sage Journals. 2023 Jul; 37(7): 707-716

Malcolm B and Thomas K. Serotonin Toxicity of Serotonergic Psychedelics. Psychopharmacology. 2022;239: 1881-1891

Perez E, et al. The Psilocybin-Blunting Effects of SSRIs and Anti-depressants. Psychedelic Passage. 3 June 2022.

Raison C, et al. Single Dose Psilocybin for Major Depressive Disorder. JAMA. 2023; 330(9): 843-853